Companies:
50,126
Total Market Cap:
141706342080389.78
Global Rank
#123
Country Rank
#72
Market Cap
142.09 B
Price
114.23
Change (%)
1.06%
Volume
6.28 M
Gilead Sciences's latest marketcap:
142.09 B
As of 07/30/2025, Gilead Sciences's market capitalization has reached $142.09 B. According to our data, Gilead Sciences is the 123th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 142.09 B |
| Revenue (ttm) | 28.74 B |
| Net Income (ttm) | 5.96 B |
| Shares Out | 1.24 B |
| EPS (ttm) | 4.73 |
| Forward PE | 14.04 |
| Ex-Dividend Date | 06/13/2025 |
| Earnings Date | 08/07/2025 |
Market Cap Chart
Data Updated: 07/30/2025
Gilead Sciences's yearly market capitalization.
Gilead Sciences has seen its market value grow from $1.25 B to $142.09 B since 1998, representing a total increase of 11,235.78% and an annual compound growth rate (CAGR) of 19.48%.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/30/2025 | $142.09 B | 22.14% | 123 |
| 12/31/2024 | $115.12 B | 14.04% | 137 |
| 12/29/2023 | $100.94 B | -6.25% | 141 |
| 12/30/2022 | $107.68 B | 18.22% | 121 |
| 12/31/2021 | $91.08 B | 24.72% | 172 |
| 12/31/2020 | $73.03 B | -11.17% | 197 |
| 12/31/2019 | $82.21 B | 1.6% | 129 |
| 12/31/2018 | $80.92 B | -13.53% | 104 |
| 12/29/2017 | $93.58 B | -0.81% | 99 |
| 12/30/2016 | $94.34 B | -35.31% | 72 |
Company Profile
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a leading biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address unmet medical needs across the United States, Europe, and internationally.
Key Product Offerings
- HIV/AIDS Treatments: Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs, and Atripla.
- COVID-19 Treatment: Veklury (intravenous injection).
- Viral Hepatitis Therapies: Epclusa, Harvoni, Vemlidy, and Viread.
- Oncology Solutions: Yescarta, Tecartus, and Trodelvy.
- Other Treatments: Letairis (pulmonary arterial hypertension) and AmBisome (invasive fungal infections).
Strategic Collaborations
Gilead partners with leading organizations to advance medical innovation, including:
- Arcus Biosciences, Inc.
- Merck Sharp & Dohme Corp.
- Galapagos NV
- Janssen Sciences Ireland Unlimited Company
- Japan Tobacco, Inc.
- Dragonfly Therapeutics, Inc.
- Merus N.V. (for trispecific antibody research)
- Terray Therapeutics, Inc. (small molecule therapies)
- LEO Pharma (STAT6 program development)
Founded: 1987 | Headquarters: Foster City, California
Frequently Asked Questions
-
What is Gilead Sciences's (GILD) current market cap?As of 07/30/2025, Gilead Sciences (including the parent company, if applicable) has an estimated market capitalization of $142.09 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Gilead Sciences (GILD) rank globally by market cap?Gilead Sciences global market capitalization ranking is approximately 123 as of 07/30/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.